Discovery of Biomarkers and Classification of Urine of Patients with Bladder Cancer And Chronic Kidney Disease

Presenter: Roland Bruderer
Date: November 7

Alterations in biofluid proteomes are powerful molecular biosignatures for the screening and diagnosis of bladder and kidney-related diseases. At HUPO 2022, Roland Bruderer presented a poster on how we identified actionable biomarkers for bladder cancer and chronic kidney disease in urine with our TrueDiscovery™ platform for deep unbiased mass-spectrometry-based proteomics.

From the total of 12,617 proteins identified in the urine samples, we revealed changes in proteins involved in programmed cell death, telomerase organization, keratinocyte, and epidermal cell differentiation, as well as inflammation markers and previously described markers such as urokinase plasminogen activator surface receptor (UPAR). Of the altered proteins analyzed, 23 significantly differentiated the pathophysiological conditions. Download the poster to discover more.